Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, has announced its participation in two major investor conferences in September 2025.
Management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET and the Morgan Stanley 23rd Annual Global Conference on September 10 at 11:30 a.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for 30 days after the events.
Relay Therapeutics (NASDAQ:RLAY), azienda clinica di medicina di precisione focalizzata sullo sviluppo di terapie per il cancro e le malattie genetiche, ha annunciato la propria partecipazione a due importanti conferenze per investitori a settembre 2025.
La direzione prenderà parte a fireside chat al 2025 Wells Fargo Healthcare Conference il 4 settembre alle 14:15 ET e al Morgan Stanley 23rd Annual Global Conference il 10 settembre alle 11:30 ET. Entrambe le presentazioni saranno trasmesse in webcast sul sito investor relations della società, con le repliche disponibili per 30 giorni dopo gli eventi.
Relay Therapeutics (NASDAQ:RLAY), una compañía clínica de medicina de precisión centrada en desarrollar terapias para el cáncer y enfermedades genéticas, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La dirección participará en charlas tipo fireside en la 2025 Wells Fargo Healthcare Conference el 4 de septiembre a las 2:15 p.m. ET y en la Morgan Stanley 23rd Annual Global Conference el 10 de septiembre a las 11:30 a.m. ET. Ambas presentaciones estarán disponibles en webcast en la web de relaciones con inversores de la compañía, con las repeticiones accesibles durante 30 días tras los eventos.
Relay Therapeutics (NASDAQ:RLAY)는 암 및 유전 질환 치료제 개발에 주력하는 임상 단계 정밀 의학 기업으로, 2025년 9월에 열리는 두 개의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다.
경영진은 2025 Wells Fargo Healthcare Conference에서 9월 4일 오후 2시 15분(ET)에, Morgan Stanley 23rd Annual Global Conference에서는 9월 10일 오전 11시 30분(ET)에 파이어사이드 챗에 참여합니다. 두 발표 모두 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 이벤트 종료 후 30일간 다시보기 서비스를 제공합니다.
Relay Therapeutics (NASDAQ:RLAY), une société en phase clinique spécialisée en médecine de précision et dédiée au développement de traitements contre le cancer et les maladies génétiques, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La direction participera à des « fireside chats » lors du 2025 Wells Fargo Healthcare Conference le 4 septembre à 14h15 ET et du Morgan Stanley 23rd Annual Global Conference le 10 septembre à 11h30 ET. Les deux présentations seront diffusées en webcast sur le site relations investisseurs de la société, avec des rediffusions accessibles pendant 30 jours après les événements.
Relay Therapeutics (NASDAQ:RLAY), ein klinisch tätiges Unternehmen für Präzisionsmedizin, das sich auf die Entwicklung von Therapien gegen Krebs und genetische Erkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 bekanntgegeben.
Das Management wird an Fireside-Chats teilnehmen: beim 2025 Wells Fargo Healthcare Conference am 4. September um 14:15 Uhr ET und beim Morgan Stanley 23rd Annual Global Conference am 10. September um 11:30 Uhr ET. Beide Präsentationen werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein; Replays sind 30 Tage nach den Veranstaltungen abrufbar.
- None.
- None.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
- 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ET
- Morgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When is Relay Therapeutics (RLAY) presenting at the Wells Fargo Healthcare Conference 2025?
When is RLAY's presentation at the Morgan Stanley Global Conference 2025?
How can investors access Relay Therapeutics' (RLAY) conference presentations?
What type of company is Relay Therapeutics (RLAY)?
